# Neo-Adjuvant Gemcitabine and Cisplatin in Treating Patients With Early Stage of Non Small Cell Lung Cancer

> **NCT00191763** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 52 (—)

## Conditions studied

- Carcinoma, Non-Small-Cell-Lung Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** cisplatin

## Key facts

- **NCT ID:** NCT00191763
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** —
- **Final completion:** 2005-12
- **Target enrollment:** 52 (—)
- **Last updated:** 2007-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00191763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00191763, "Neo-Adjuvant Gemcitabine and Cisplatin in Treating Patients With Early Stage of Non Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00191763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*